Expanding To Develop & Deliver Tomorrow's Cures

To meet growing demand for late-stage clinical and commercial cell therapy manufacturing, a major facility expansion is underway, strengthening both physical infrastructure and operational capabilities. The expansion is designed to support the transition of therapies from development into commercialization by increasing cleanroom capacity, enhancing quality control laboratories, and improving overall process integration.

Key additions include new ISO-classified cleanroom suites, expanded microbiology and quality control labs, and upgraded digital systems to support scalable program management and data integrity. A dedicated process science and technology laboratory further enables late-stage process characterization, validation, and technology transfer, ensuring programs are optimized for commercial readiness.

Together, these enhancements provide greater manufacturing flexibility, faster product release timelines, and improved lifecycle support. By integrating advanced infrastructure with specialized expertise, the expansion creates a robust foundation for scaling complex therapies efficiently and reliably toward commercialization.